HUTCHMED DRC (NASDAQ: HCM) — Perfil da empresa, notícias e dados financeiros
HUTCHMED is a global biopharmaceutical company focused on targeted therapies and immunotherapies for cancer treatments.
HUTCHMED DRC
HUTCHMED (HKEX:0013), (NASDAQ:HCM) is a global biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company is known for its robust pipeline of innovative drug candidates, several of which are in advanced stages of clinical trials with the aim of addressing unmet medical needs across various regions. HUTCHMED is committed to advancing healthcare by developing highly effective treatments, with a focus on bringing novel solutions to patients worldwide. The company actively collaborates with academic, industrial, and healthcare partners to expand its reach and impact in the healthcare sector.
Resumo
Operações
Produtos e/ou serviços de HUTCHMED DRC
- Oncology treatments focused on inhibiting cancer cell growth
- Targeted therapies for solid tumors and hematologic malignancies
- Research and development in tyrosine kinase inhibitors
- Global partnerships for drug discovery and development
- Manufacturing services for pharmaceutical products
- Clinical trial management and execution services
equipe executiva do HUTCHMED DRC
- Chig Fung ChengActing CEO, CFO & Executive Director
- Wei-Guo SuCEO, Chief Scientific Officer & Executive Director (Leave of Absence)
- Yiling CuiExecutive VP & Head of Operations
- Xinhui HuExecutive Vice President & Chief Technical Officer
- David NgHead of Investor Relations & Capital Strategies
- Charles George Rupert NixonGroup General Counsel
- Kin Hung LeeSenior Vice President of Corporate Management & Communications
- Selina ZhangSenior Vice President of Global Human Resources
- Qingmei WangExecutive Vice President of Business Development & Strategic Alliances
- Thomas FuSenior Vice President of Global Quality
Últimas notícias sobre a HUTCHMED DRC
HUTCHMED lung cancer treatment filings advance
United StatesHUTCHMED wins FDA orphan designation for sovleplenib
United StatesHUTCHMED Phase III trial cuts progression risk 44%
United StatesHUTCHMED reports 32% lower death risk in lung cancer trial
United StatesHUTCHMED closes $1.3 billion GSK cancer drug licensing deal
United StatesHUTCHMED advances ORPATHYS lung cancer application
United States
Principais indicadores financeiros
Resultados divulgados pela HUTCHMED DRC, em USD.
- Cap. de mercado
- 2,7 bi
- Receita (TTM)
- 549,1 mi
- P/L
- 153.2
- LPA (diluído, TTM)
- 0.1
- Dividend yield
- —
- Margem de lucro
- 3.3%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 550 mi | -54,7 mi | 458,1 mi | |
| 630,2 mi | -43,7 mi | 37,7 mi | |
| 838 mi | 18,4 mi | 100,8 mi | |
| 426,4 mi | -718,8 mi | -360,8 mi |